Feb. 20, 2020 13:15 UTC SAN DIEGO--( BUSINESS WIRE )-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2019. As of December 31, 2019, Odonate had $180.5 million in cash, compared to $139.1 million as of December 31, 2018. This increase in cash resulted pri
February 20, 2020
· 10 min read